OPKO Health Inc.

Report Publication Announcement • Aug 3, 2017

OPKO Health to Announce 2017 Second Quarter Financial Results on August 8, 2017

MIAMI (August 3, 2017) – OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months and six months ended June 30, 2017, after the close of the U.S. financial markets on Tuesday, August 8, 2017.

OPKO's senior management will provide a business update and discuss its financial results in a conference call and live audio webcast beginning at 4:30 p.m. Eastern time on Tuesday, August 8, 2017.

Conference Call & Webcast Information

WHEN: Tuesday, August 8, 2017, 4:30 p.m. Eastern time. DOMESTIC DIAL-IN: (866) 634-2258 INTERNATIONAL DIAL-IN: (330) 863-3454 PASSCODE: 65755948 WEBCAST:http://investor.opko.com/events.cfm

For those unable to participate in the live conference call or webcast, a replay will be available beginning August 8, 2017 two hours after the close of the conference call. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 65755948. The replay can be accessed for a period of time on OPKO's website at http://investor.opko.com/events.cfm.

About OPKO Health, Inc.

OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and OPK88004, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer), and a long acting Factor VIIa drug for hemophilia in Phase 2a. More information available at www.opko.com.

Contacts:

OPKO Health, Inc. David Malina, 305-575-4137 Investor Relations dmalina@opko.com

Or

Investors LHA Anne Marie Fields, 212-838-3777 afields@lhai.com Or Bruce Voss, 310-691-7100 bvoss@lhai.com

#